David Roman
Stock Analyst at Goldman Sachs
(1.87)
# 3,145
Out of 4,918 analysts
44
Total ratings
37.5%
Success rate
-5.42%
Average return
Main Sectors:
Stocks Rated by David Roman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OMDA Omada Health | Initiates: Buy | $29 | $17.84 | +62.56% | 1 | Jul 1, 2025 | |
| HQY HealthEquity | Maintains: Neutral | $94 → $104 | $91.05 | +14.22% | 3 | Jun 4, 2025 | |
| BBNX Beta Bionics | Initiates: Neutral | $16 | $16.42 | -2.56% | 1 | May 30, 2025 | |
| PODD Insulet | Initiates: Buy | $380 | $287.77 | +32.05% | 1 | May 30, 2025 | |
| DOCS Doximity | Maintains: Neutral | $80 → $50 | $58.30 | -14.24% | 3 | May 21, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Neutral | $120 → $104 | $92.40 | +12.55% | 2 | May 6, 2025 | |
| TDOC Teladoc Health | Maintains: Buy | $13 → $10 | $6.97 | +43.47% | 4 | May 1, 2025 | |
| GEHC GE HealthCare Technologies | Maintains: Buy | $94 → $82 | $70.64 | +16.08% | 3 | May 1, 2025 | |
| KMTS Kestra Medical Technologies | Maintains: Neutral | $24 → $23 | $15.48 | +48.58% | 2 | Apr 16, 2025 | |
| ABT Abbott Laboratories | Maintains: Buy | $138 → $154 | $129.93 | +18.53% | 2 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $42 → $24 | $15.42 | +55.64% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $63 → $71 | $73.22 | -3.03% | 4 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $64 → $55 | $42.78 | +28.56% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $42 | $22.44 | +87.17% | 3 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $91 → $124 | $164.98 | -24.84% | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $384 → $427 | $381.49 | +11.93% | 2 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $81 → $90 | $80.09 | +12.37% | 3 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $90 | $106.79 | -15.72% | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $500 | $483.36 | +3.44% | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $274 | $178.90 | +53.16% | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $83 | $89.64 | -7.41% | 1 | May 30, 2024 |
Omada Health
Jul 1, 2025
Initiates: Buy
Price Target: $29
Current: $17.84
Upside: +62.56%
HealthEquity
Jun 4, 2025
Maintains: Neutral
Price Target: $94 → $104
Current: $91.05
Upside: +14.22%
Beta Bionics
May 30, 2025
Initiates: Neutral
Price Target: $16
Current: $16.42
Upside: -2.56%
Insulet
May 30, 2025
Initiates: Buy
Price Target: $380
Current: $287.77
Upside: +32.05%
Doximity
May 21, 2025
Maintains: Neutral
Price Target: $80 → $50
Current: $58.30
Upside: -14.24%
Zimmer Biomet Holdings
May 6, 2025
Maintains: Neutral
Price Target: $120 → $104
Current: $92.40
Upside: +12.55%
Teladoc Health
May 1, 2025
Maintains: Buy
Price Target: $13 → $10
Current: $6.97
Upside: +43.47%
GE HealthCare Technologies
May 1, 2025
Maintains: Buy
Price Target: $94 → $82
Current: $70.64
Upside: +16.08%
Kestra Medical Technologies
Apr 16, 2025
Maintains: Neutral
Price Target: $24 → $23
Current: $15.48
Upside: +48.58%
Abbott Laboratories
Mar 4, 2025
Maintains: Buy
Price Target: $138 → $154
Current: $129.93
Upside: +18.53%
Mar 3, 2025
Maintains: Neutral
Price Target: $42 → $24
Current: $15.42
Upside: +55.64%
Mar 3, 2025
Maintains: Sell
Price Target: $63 → $71
Current: $73.22
Upside: -3.03%
Mar 3, 2025
Maintains: Buy
Price Target: $64 → $55
Current: $42.78
Upside: +28.56%
Feb 26, 2025
Reinstates: Buy
Price Target: $42
Current: $22.44
Upside: +87.17%
Feb 24, 2025
Maintains: Neutral
Price Target: $91 → $124
Current: $164.98
Upside: -24.84%
Jan 30, 2025
Maintains: Neutral
Price Target: $384 → $427
Current: $381.49
Upside: +11.93%
Dec 5, 2024
Maintains: Buy
Price Target: $81 → $90
Current: $80.09
Upside: +12.37%
May 30, 2024
Initiates: Buy
Price Target: $90
Current: $106.79
Upside: -15.72%
May 30, 2024
Initiates: Buy
Price Target: $500
Current: $483.36
Upside: +3.44%
May 30, 2024
Initiates: Buy
Price Target: $274
Current: $178.90
Upside: +53.16%
May 30, 2024
Initiates: Sell
Price Target: $83
Current: $89.64
Upside: -7.41%